Affinivax Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 200

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $3B

  • Investors
  • 1

Affinivax General Information

Description

Operator of a vaccine development company intended to enhance the depth and breadth of protection against challenging infectious diseases. The company's vaccine development features a patented approach to achieve high-affinity binding of two key immunogenic components, polysaccharide and protein antigens so that both components are able to drive abroad and protective B-cell and T-cell immune response in a single vaccine, enabling doctors to develop preventive and therapeutic vaccines that provide broader protection against infectious and other immune-mediated diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 301 Binney Street
  • Suite 302
  • Cambridge, MA 02142
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 301 Binney Street
  • Suite 302
  • Cambridge, MA 02142
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Affinivax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 15-Aug-2022 $3B Completed Clinical Trials - General
5. Later Stage VC (Series C) 03-May-2021 Completed Clinical Trials - General
4. Later Stage VC (Series B) 23-Apr-2020 Completed Clinical Trials - General
3. Early Stage VC (Series A) 05-Jan-2018 Completed Clinical Trials - General
2. Early Stage VC 05-Feb-2016 $2.5M $6.5M Completed Clinical Trials - General
1. Seed Round 30-Oct-2014 $4M $4M Completed Clinical Trials - General
To view Affinivax’s complete valuation and funding history, request access »

Affinivax Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series C-1
Series B 8,452,884 $0.000100 $14.22 $14.22 1x $14.22 24.55%
Series A 3,068,305 $0.000100 $2.28 $2.28 1x $2.28 8.93%
To view Affinivax’s complete cap table history, request access »

Affinivax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a vaccine development company intended to enhance the depth and breadth of protection against challenging in
Drug Discovery
Cambridge, MA
200 As of 2022

Atlanta, GA
 

Antwerp, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Affinivax Competitors (31)

One of Affinivax’s 31 competitors is Micron Biomedical, a Venture Capital-Backed company based in Atlanta, GA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Micron Biomedical Venture Capital-Backed Atlanta, GA
AgomAb Venture Capital-Backed Antwerp, Belgium
Alzheon Venture Capital-Backed Framingham, MA
Quince Therapeutics Formerly VC-backed South San Francisco, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
You’re viewing 5 of 31 competitors. Get the full list »

Affinivax Patents

Affinivax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230091255-A1 Multivalent pneumococcal vaccines Active 09-Sep-2021
CA-3231684-A1 Multivalent pneumococcal vaccines Pending 09-Sep-2021
AU-2022342080-A1 Multivalent pneumococcal vaccines Pending 09-Sep-2021
US-12036276-B2 Multivalent pneumococcal vaccines Active 09-Sep-2021
US-20240398924-A1 Multivalent pneumococcal vaccines Pending 09-Sep-2021 A61K39/092
To view Affinivax’s complete patent history, request access »

Affinivax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Affinivax Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bain Capital Life Sciences Corporate Venture Capital Minority
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital Minority
BlackRock Asset Manager Minority
CARB-X University Minority
Citadel Enterprise Americas Hedge Fund Minority
You’re viewing 5 of 16 investors. Get the full list »

Affinivax FAQs

  • When was Affinivax founded?

    Affinivax was founded in 2014.

  • Where is Affinivax headquartered?

    Affinivax is headquartered in Cambridge, MA.

  • What is the size of Affinivax?

    Affinivax has 200 total employees.

  • What industry is Affinivax in?

    Affinivax’s primary industry is Drug Discovery.

  • Is Affinivax a private or public company?

    Affinivax is a Private company.

  • What is the current valuation of Affinivax?

    The current valuation of Affinivax is .

  • What is Affinivax’s current revenue?

    The current revenue for Affinivax is .

  • How much funding has Affinivax raised over time?

    Affinivax has raised $359M.

  • Who are Affinivax’s investors?

    Bain Capital Life Sciences, Bill & Melinda Gates Foundation, BlackRock, CARB-X, and Citadel Enterprise Americas are 5 of 16 investors who have invested in Affinivax.

  • Who are Affinivax’s competitors?

    Micron Biomedical, AgomAb, Alzheon, Quince Therapeutics, and Kite Pharma are some of the 31 competitors of Affinivax.

  • When was Affinivax acquired?

    Affinivax was acquired on 15-Aug-2022.

  • Who acquired Affinivax?

    Affinivax was acquired by GSK.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »